Drug Trial Radar · NCT01127620
Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension
Last checked: Nov 20, 2026Latest source record: Sep 26, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
650
Actual
Start
May 2004
Primary completion
Mar 2006
Study completion Nov 2006
Sponsor
- Lead sponsor
- Faes Farma, S.A.Industry
- Sponsor type
- Industry
- First posted
- May 21, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Double-blind phase: The objective of the study was to evaluate the efficacy and safety of Bilastine 20 mg, compared to Cetirizine and placebo for the treatment of perennial allergic rhinitis. Open-label Phase: The objective of this extension was to evaluate the long-term safety of Bilastine 20 mg during one year in the symptomatic treatment of perennial allergic rhinitis
Conditions
- Perennial Allergic Rhinitis
Interventions
BilastineDrug
20 mg encapsulated tablets
CetirizineDrug
10 mg encapsulated tablets
PlaceboDrug
encapsulated tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double-blind phase: AUC of TSS throughout the studyTime frame: 28 days
- Open-label phase: Long-term safetyTime frame: 12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.